Impact of hematologic complete response in the treatment of sporadic late-onset nemaline myopathy associated with monoclonal gammopathy
- PMID: 34295490
- PMCID: PMC8283848
- DOI: 10.1002/ccr3.4471
Impact of hematologic complete response in the treatment of sporadic late-onset nemaline myopathy associated with monoclonal gammopathy
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) may be associated with pathologies with severe neuromuscular manifestations such as sporadic late-onset nemaline myopathy (SLONM). We describe a difficult to diagnose case of SLNOM with marked clinical improvement after achieving gammopathy complete hematologic response.
Keywords: autologous stem cell transplant; monoclonal gammopathy of undetermined significance; sporadic late‐onset nemaline myopathy.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
RB: grants from Celgene, SPH/APCL/Amgen; advisory board and speaker honoraria from Celgene, Janssen, Takeda and Amgen. FT: grant SPH/APCL/Amgen; advisory board and speaker honoraria from Celgene, Janssen, Takeda and Amgen.
Figures



References
-
- Kuwabara S, Misawa S, Kanai K, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology. 2006;66(1):105‐107. - PubMed
-
- Belhomme N, Maamar A, Le Gallou T, et al. Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy. Ann Hematol. 2017;96(4):695‐696. - PubMed
-
- Fermand J‐P, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478‐1485. - PubMed
-
- Chahin N, Selcen D, Engel AG. Sporadic late onset nemaline myopathy. Neurology. 2005;65(8):1158‐1164. - PubMed
Publication types
LinkOut - more resources
Full Text Sources